ICD10BillableValid for clinical use

ICD-10 Code E88.13: Localized lipodystrophy

E88.13 is a billable ICD-10 diagnosis code used to classify Localized lipodystrophy in medical records and claims. You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records. ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

What is this code?

ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

šŸ“‹Clinical overview

This code records localized lipodystrophy and retains injection lipodystrophy and insulin lipodystrophy as inclusion examples. Those examples do not establish that an individual uses insulin, has diabetes, receives a particular medicine or has a change at a particular injection site. Localized does not mean inherited generalized disease, nor does it prove that a change is harmless. Understanding what was documented requires the person's actual history and examination. The page preserves the original notes, Index and qualified service associations without turning them into a treatment plan.

When is it used?

  • May be used when a clinician documents localized lipodystrophy in a patient's medical record.
  • May appear in hospital records, claims, referrals, and clinical documentation.
  • This code can be used as a clinically usable diagnosis entry in standardized coding workflows.

What it does not mean

  • A code alone does not explain severity, treatment plan, or outcome.
  • A medical code should not be treated as a substitute for a doctor's diagnosis or advice.

🩺Clinical context

When commonly used
  • Localized describes the classification context, not an exact site, lesion size, cause or severity measurement. The inclusion examples are not a complete personal medicine history and do not show that every localized change is related to an injection. Ask which finding the clinician recorded and how it was interpreted. This entry is different from partial and generalized categories, and an educational explanation should not add a genetic syndrome, systemic metabolic problem or exposure solely because those subjects appear elsewhere in the lipodystrophy branch.
  • The selected NOVOLIN R label describes fat thinning and fat thickening in an insulin injection context. It also explains that insulin absorption and glucose control may be affected when a regimen or injection site changes. This is a product-specific safety example, not proof that the reader uses that product or that every localized lipodystrophy is insulin-related. The label separately discusses localized cutaneous amyloidosis; a related location or appearance does not make those terms automatically the same diagnosis on this page.
  • Injection lipodystrophy and Insulin lipodystrophy remain the two literal local inclusion terms. The local code-first, additional-code and exclusion arrays remain empty. The broader E88 associated-condition note and E88.1 Whipple exclusion keep their ancestor roles; neither creates a personal diabetes, drug-adverse-effect or additional-code assignment here. A medicine label describes a named product's context rather than final US diagnosis coding. The clinical and coding teams should clarify the actual record rather than recoding it from an educational example.
  • The original E88.1 parent and neighboring entries provide classification navigation, not a collection of extra conditions. Six SNOMED relationships belong to the parent, with their original directions, source snapshot and additional-code or external-cause qualifiers. They do not establish an AKT2- or CIDEC-related disorder, a laminopathy, an acquired cause or a congenital condition on this leaf. Shared chapter excerpts concerning diabetes, pregnancy or obesity also do not diagnose those conditions in a reader. Keep navigation, qualified associations and the personal clinical account distinct.
Common workup
  • Discuss the actual location, timing and clinical account of the localized change, including any real medicines or injections the responsible team considers relevant. Do not fill those details from the inclusion terms. Ask what examination findings support the recorded interpretation and whether a different local problem needs consideration. The code does not establish skin integrity, an infection, an injection error, a medicine reaction or a completed assessment. The preserved facial-filler association is also not evidence that the documented finding is on the face.
  • Clarify the clinical question behind any proposed investigation rather than treating this entry as a request for metabolic, genetic or cardiac screening. A named insulin-label example does not show that a glucose result is abnormal, and a related ECG service does not establish that an ECG was performed. The page cannot decide which investigations, if any, are appropriate for an actual localized finding. Ask how the history and examination guide the next step and how any result would be explained in that person's context.
  • This leaf retains G0429, three routine ECG associations, Q2026 and Q2028 in their original order and article contexts. The ECG rows distinguish tracing, interpretation/report and the combined service; they are not findings or a compulsory workup. G0429's facial/antiretroviral example does not establish facial involvement or treatment exposure in an individual. Q2026 describes RADIESSE in a 0.1 ML billing unit, and Q2028 describes SCULPTRA in a 0.5 MG unit. Those literal units are not administered doses, a product choice or proof of eligibility or current coverage.
  • When reviewing an existing report or proposed assessment, ask what was actually observed, what question remains open and who will explain the result. A code title, inclusion example or service description is not the result of that assessment. Missing information is not automatically a normal finding, and the absence of a particular related link does not establish that an investigation is unnecessary. The page cannot provide a diagnostic checklist for every subtype or a universal schedule; the clinical reason and documented context should remain visible.
Common management context
  • If the actual concern involves insulin injections, discuss it with the team managing that medicine before changing the regimen or injection-site practice independently. The selected label emphasizes medical supervision because changes can affect glucose control. This page does not select a dose, product, device, injection technique, rotation pattern or replacement site. If insulin is not part of the person's actual history, the inclusion example should not be turned into a new medicine exposure or diabetes diagnosis. Care still needs the real localized finding and the responsible clinician's assessment.
  • Ask who should review the localized concern and explain any existing instructions, particularly when a medicine or injection is genuinely involved. Keep records of what was actually observed and what the prescribing team advised, rather than using a billing label to infer a procedure or location. The code provides no recovery deadline, monitoring frequency or expected response to changing a product. A new concern should be discussed in its actual clinical setting; the classification is not a substitute for a personal safety or follow-up plan.
  • An educational code page cannot determine the cause or urgency of a new health concern. Discuss a changing concern with the responsible clinical team and use the personal safety instructions they have provided; do not wait for a code or terminology question to be settled if medical attention is needed. This explanation does not replace assessment, establish that a symptom is harmless or supply a home rule for excluding another problem. Existing prescribed medicines and any changes to them require the appropriate treating team.
  • A useful shared discussion separates the documented problem, the goal of a proposed measure, the evidence applicable to that person and the arrangements for review. Ask which uncertainties remain and what alternatives need consideration. Neither an entry in this classification branch nor a historical research result selects a medicine, a dose, a dietary target, a genetic test, a cosmetic injection or an operation. No service association guarantees access, reimbursement or benefit, and no general reference promises a particular recovery or treatment response.

šŸ”Key distinctions

Important notes
  • The subtype distinctions do not establish a cause, gene, affected region, severity or an individual result. Partial and generalized contexts include both inherited and acquired examples; localized injection examples do not establish exposure. The grouping parent remains unchanged.
  • HIV-associated coding retains its code-first note and conditional adverse-effect wording. Those notes do not establish a drug cause, and a displayed incomplete stem is not a final encounter code. Parent notes and clinical-source terminology do not become extra diagnoses or silent repairs.
  • Qualified ECG and facial-filler associations remain billing context, not a prescribed workup, procedure performed, product indication, administered dose, eligibility or present coverage. Relevant references are selected separately for each leaf; no shared treatment pathway is assigned.
  • Three exact stored Index routes remain: Lipodystrophy > injection, Lipodystrophy > insulin and Lipodystrophy > localized. These are classification routes, not proof of exposure, a specified product, a site or a procedure performed. The surrounding partial, generalized and HIV-associated entries are navigation alternatives rather than additional diagnoses. No new brand synonym, medication history, affected location or related skin diagnosis is inserted into the original arrays.
  • The selected NOVOLIN R label was updated in November 2022 and is used only for its named injection-site safety context. It is not a current comprehensive guideline for all localized lipodystrophy or evidence of present product use. The CMS material is historical FY2026 coding context, distinct from the pinned FY2027 book cross-check. Neither reference changes the stored release, certifies current coverage or supplies an individualized prescribing decision.
  • All original notes, exclusions, inclusion terms, Index arrays, hierarchy, synonyms, URLs, source metadata, priorities, review flags, specialists, overrides, semantic caches and qualified service relationships remain available in their original places. This educational addition removes none of them and does not silently repair terminology, relationships or coding data. Reference selection is specific to the leaf: inherited, acquired, injection-related and HIV-associated examples are not presented as one common disease mechanism or treatment pathway. This is not individual clinical signoff or a current payment decision.
Related codes to consider
E88.10Lipodystrophy, unspecified
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.11Partial lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.12Generalized lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.14HIV-associated lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.

Code hierarchy

chapter
4Endocrine, nutritional and metabolic diseases (E00-E89)
block
E70-E88Metabolic disorders
category
E88Other and unspecified metabolic disorders
category
E88.1Lipodystrophy, not elsewhere classified
currentE88.1

Official coding notes

Inclusion terms
  • Injection lipodystrophy
  • Insulin lipodystrophy

Where you may see this code

You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records.

Related specialists

EndocrinologistGeneral Physician

Coding guidelines

Common synonyms

Localized lipodystrophy

Frequently asked questions

Code details

CodeE88.13
SystemICD10
Display nameLocalized lipodystrophy
ChapterEndocrine, nutritional and metabolic diseases (E00-E89)
BlockMetabolic disorders

Flags

BillableYes
Valid clinical useYes

Source

SourceICD-10
Version2026-annual
Releaseannual
Year2026

Index terms

Matched terms
LipodystrophyLipodystrophyLipodystrophy

About this content

This page is prepared by HealthAssure's clinical team using official coding standards from ICD-10. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.